- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics Inc stock price live, this page displays NASDAQ ESPR stock exchange data. View the ESPR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Esperion Therapeutics Inc real time stock price chart below.
What Is the Esperion Therapeutics Inc Stock Price Today?
The Esperion Therapeutics Inc stock price today is 2.935.
What Is the Stock Symbol for Esperion Therapeutics Inc?
The stock symbol for Esperion Therapeutics Inc is "ESPR."
What Stock Exchange Does Esperion Therapeutics Inc Trade On?
Esperion Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Esperion Therapeutics Inc a Good Stock to Buy?
Determining whether Esperion Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ESPR quote. (ISIN: US29664W1053)
What Is the Esperion Therapeutics Inc Stock Price Today?
The Esperion Therapeutics Inc stock price today is 2.935.
What Is the Stock Symbol for Esperion Therapeutics Inc?
The stock symbol for Esperion Therapeutics Inc is "ESPR."
What Stock Exchange Does Esperion Therapeutics Inc Trade On?
Esperion Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Esperion Therapeutics Inc a Good Stock to Buy?
Determining whether Esperion Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ESPR quote. (ISIN: US29664W1053)
2.935
-0.105(-3.45%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.860
2.980
52 wk Range
0.693
4.175
ESPR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.8602.980
52 wk Range
0.6934.175
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ESPR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
6.501
Upside
+121.51%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock has taken a big hit over the last week
- Esperion Th receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- AMD, Merck among market cap stock movers on Tuesday
- Investing.com
- AMD, Nvidia among market cap stock movers on Tuesday
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Esperion Therapeutics Inc Company Profile
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics Inc Earnings Call Summary for Q3/2025
- Esperion Therapeutics reported Q3 2025 EPS of -$0.16 (vs $0.02 forecast) and revenue of $87.3M (vs $92.5M expected), triggering a 4.08% pre-market stock decline to $2.82.
- Despite missing forecasts, total revenue grew 69% YoY, with U.S. product revenue up 31% to $40.7M and collaboration revenue surging 128% to $46.7M.
- Operating expenses increased with R&D up 36% to $14.1M and SG&A expenses rising 5% to $41.8M, with full-year 2025 operating expenses projected at $215-235M.
- CEO Sheldon Koenig highlighted 'strong execution and growing momentum' as the company pursues U.S. guideline inclusion and prepares to launch Vision 2040.
- Management aims to achieve sustainable profitability by Q1 2026 and is exploring market entry in Japan with Otsuka Pharmaceutical despite current earnings challenges.
Last Updated: 2025-11-06, 09:02 a/m
Read Full TranscriptCompare ESPR to Peers and Sector
Metrics to compare | ESPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipESPRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.6x | 11.2x | −0.6x | |
PEG Ratio | 2.46 | 0.14 | 0.00 | |
Price/Book | −1.5x | 2.5x | 2.6x | |
Price / LTM Sales | 2.3x | 2.1x | 3.4x | |
Upside (Analyst Target) | 52.8% | 172.9% | 41.5% | |
Fair Value Upside | Unlock | 31.9% | 5.5% | Unlock |
Analyst Ratings
6 Buy
1 Hold
1 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.501
(+121.51% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.16 / 0.02
Revenue / Forecast
87.30M / 92.50M
People Also Watch
FAQ
What Is the Esperion (ESPR) Stock Price Today?
The Esperion stock price today is 2.935
What Stock Exchange Does Esperion Trade On?
Esperion is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Esperion?
The stock symbol for Esperion is "ESPR."
What Is the Esperion Market Cap?
As of today, Esperion market cap is 696.87M.
What Is Esperion's Earnings Per Share (TTM)?
The Esperion EPS (TTM) is -0.54.
When Is the Next Esperion Earnings Date?
Esperion will release its next earnings report on Feb 24, 2026.
From a Technical Analysis Perspective, Is ESPR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Esperion Stock Split?
Esperion has split 0 times.
How Many Employees Does Esperion Have?
Esperion has 304 employees.
What is the current trading status of Esperion (ESPR)?
As of Jan 20, 2026, Esperion (ESPR) is trading at a price of 2.935, with a previous close of 3.040. The stock has fluctuated within a day range of 2.860 to 2.980, while its 52-week range spans from 0.693 to 4.175.
What Is Esperion (ESPR) Price Target According to Analysts?
The average 12-month price target for Esperion is USD6.501, with a high estimate of USD16 and a low estimate of USD1.72. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +121.51% Upside potential.
What Is the ESPR Premarket Price?
ESPR's last pre-market stock price is 2.910. The pre-market share volume is 96,800.000, and the stock has decreased by -0.130, or -4.280%.
What Is the ESPR After Hours Price?
ESPR's last after hours stock price is 3.010, the stock has decreased by -0.030, or -0.990%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.